ESC Congress 2022 Barcelona, Onsite & Online, 26 - 29 August

We are delighted to announce that ESC Congress will welcome you back from 26 to 29 August 2022 - onsite in Barcelona and online, around the globe.

We invite you to start your journey to the 'Magic of Cardiology'.

Hot Line Presentations at ESC Congress 2022 

European Society of Cardiology Annual Conference will showcase the latest data in cardiology.

Below are the hot line science presentations that will be presented at ESC Congress 2022 in Barcelona.

26 August 2022

HOT LINE SESSION 1

TIME - The Treatment in Morning versus Evening study

Presented by Thomas MacDonald (University of Dundee, Dundee, UK)

A polypill strategy in secondary prevention: results of the SECURE trial

Presented by Valentin Fuster (Mount Sinai Health System, New York, US)

PERSPECTIVE - Sacubitril/valsartan and cognitive function in HFmrEF and HFpEF

Presented by John J V McMurray (Western Infirmary, Glasgow, UK)

27 August 2022

HOT LINE SESSION 2 

DANCAVAS - Screening and intervention to prevent cardiovascular disease

Presented by Axel Cosmus Pyndt Diederichsen (Odense University Hospital, Odense, DK)

ADVOR - Acetazolamide in acute heart failure

Presented by Wilfried Mullens (Hospital Oost-Limburg (ZOL), Genk, BE)

DANFLU-1 - High-dose vs. standard-dose quadrivalent influenza vaccine in elderly adults

Presented by Niklas Dyrby Johansen (Herlev and Gentofte Hospital, Copenhagen, DK) 

BOX - Oxygen therapy in comatose OHCA patients

Presented by Jacob Eifer Moller (Rigshospitalet-Copenhagen University Hospital - Copenhagen, DK)

BOX - Optimizing blood pressure in post-resuscitation care

Presented by Jesper Kjaergaard (Rigshospitalet - Copenhagen University Hospital - Copenhagen, DK)

27 August 2022

HOT LINE SESSION 3

REVIVED - Percutaneous Revascularisation for Ischaemic Ventricular Dysfunction

Presented by Divaka Perera (Guy's & St Thomas' NHS Foundation Trust, London, UK)

ALL-HEART - Allopurinol and cardiovascular outcomes in ischaemic heart disease

Presented by Isla Shelagh Mackenzie (University of Dundee, Dundee, UK)

EchoNet-RCT - Safety and Efficacy Study of AI LVEF

Presented by David Ouyang (Cedars-Sinai Smidt Heart Institute, Los Angeles, US)

27 August 2022

HOT LINE SESSION 4

SGLT2 inhibition in heart failure 

DELIVER - Dapagliflozin in Heart Failure with Mildly Reduced and Preserved Ejection Fraction

Presented by Scott Solomon (Brigham and Women’s Hospital, Harvard Medical School, Boston, US) 

Pooled analysis of DAPA-HF and DELIVER

Presented by Pardeep Jhund (University of Glasgow, Glasgow, UK) 

A Pre-Specified Meta-Analysis of DELIVER and EMPEROR-Preserved

Presented by Pardeep Jhund (University of Glasgow, Glasgow, UK) 

28 August 2022

HOT LINE SESSION 5

INVICTUS - Rivaroxaban versus VKA for rheumatic atrial fibrillation

Presented by Ganesan Karthikeyan (All India Institute of Medical Sciences (AIIMS) - New Delhi, IN)

PACIFIC-AMI - Efficacy and safety of factor XIa inhibitor asundexian on top of dual antiplatelet therapy after acute myocardial infarction

Presented by John Alexander (Duke University Medical Center, Durham, US)

PACIFIC-STROKE - Phase 2 Program of AntiCoagulation via Inhibition of FXIa by the oral Compound BAY 2433334 – non-cardioembolic STROKE study

Presented by Ashkan Shoamanesh (Hamilton, Canada)

AXIOMATIC-SSP: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention

Presented by Mukul Sharma (Mcmaster University, Ontario, CA)

28 August 2022

HOT LINE SESSION 6

eBRAVE-AF - Smartphone-based AF screening

Presented by Axel Bauer (Innsbruck Medical University, Innsbruck, AT)

Causal AI substantially improves the validity of estimating cardiovascular risk and benefit

Presented by Brian A Ference (University of Cambridge, Cambridge, UK)

AI-ENHANCED detection of Aortic Stenosis

Presented by Geoffrey Strange (University of Sydney, Sidney, AU)

28 August 2022

HOT LINE SESSION 7

DanNICAD-2 - Perfusion scanning with MR or PET after a positive CT coronary angiography

Presented by Morten Bottcher (Aarhus University, Aarhus, DK)

The PRE18FFIR Trial: Coronary Plaque Activity to Predict Recurrent Events.

Presented by David Newby (University of Edinburgh, Edinburgh, UK)

The FRAME-AMI trial - FFR vs. Angiography-guided PCI in AMI with multivessel disease

Presented by Joo-Yong Hahn (Samsung Medical Center, Seoul, KR)

29 August 2022

HOT LINE SESSION 8

Important clinical trial updates 

ISCHEMIA-CKD EXTEND - Clinical Outcomes at 5 years of Follow-up

Presented by Sripal Bangalore (New York University School of Medicine, New York, US)

15-month results of the MASTER DAPT trial

Presented by Marco Valgimigli (Cardiocentro Ticino Foundation, Lugano, CH)

FOURIER-OLE: Primary Results

Presented by Michelle O'Donoghue (Brigham and Women's Hospital, Boston, US)

FIDELITY: Causes of mortality

Presented by Gerasimos Filippatos (National & Kapodistrian University of Athens Medical School, Athens, GR)

PARADISE-MI Trial - Win Ratio Analysis

Presented by Otavio Berwanger (Heart Hospital (HCor), Sao Paulo, BR)

29 August 2022

HOT LINE SESSION 9

Evidence synthesis on clinically important questions 

CTT meta-analysis of the effects of statins on muscle symptoms.

Presented by Colin Baigent (University of Oxford, Oxford, UK)

MTT - Assessing the effects of ARBs and beta-blockers in Marfan Syndrome.

Presented by Alex Pitcher (University of Oxford, Oxford, UK)

PANTHER - P2Y12 inhibitor versus aspirin monotherapy in patients with coronary artery disease.

Presented by Marco Valgimigli (Cardiocentro Ticino Foundation, Lugano, CH) 

RTC - Radial versus femoral access for coronary procedures.

Presented by Giuseppe Gargiulo (Federico II University Hospital, Naples, IT)

29 August 2022

HOT LINE SESSION 9

COVID-PACT - Antithrombotic therapy in critically Ill COVID-19 patients

Presented by David Berg (Brigham and Women's Hospital, Boston, US) 

ACT Outpatient Trial

Presented by John William Eikelboom (McMaster University, Hamilton, CA)

ACT Inpatient Trial

Presented by Sanjit Jolly (Population Health Research Institute, Hamilton, CA)